Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 6

Molecular targeted therapies in metastatic melanoma

Authors Chakraborty R, Wieland CN, Comfere NI

Received 5 March 2013

Accepted for publication 7 May 2013

Published 7 June 2013 Volume 2013:6 Pages 49—56


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Rima Chakraborty,1 Carilyn N Wieland,2 Nneka I Comfere2

1University of Missouri-Kansas City Medical School, Kansas City, MO, 2Departments of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Abstract: The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns.

Keywords: BRAF inhibitors, metastatic melanoma, personalized medicine

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.